Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » SpeeDx, LabCorp Will Codevelop MDx Tests

SpeeDx, LabCorp Will Codevelop MDx Tests

Jan 13, 2020
|
staff reporter

NEW YORK – SpeeDx said on Monday it has agreed with Laboratory Corporation of America to codevelop diagnostic tests . The agreement focuses on assays for women's health and infectious diseases.

SpeeDx and LabCorp will work together to codevelop and introduce new molecular tests using SpeeDx's proprietary technology, the Australia-based firm said in an email. Financial terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Another Protocol Released

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

From Just Some Blood

Time magazine looks into how liquid biopsies are changing cancer care.

Numerous Countries Agree to Vaccine Plan

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

PNAS Papers on Hypertrophic Cardiomyopathy, Major Depression, Spanish SARS-CoV-2 Cat

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

What's Popular?

In Business News

  1. Illumina to Acquire Grail for $8B in Cash and Stock

  2. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  3. Biocept Lung Cancer Liquid Biopsy Test Obtains Coverage From Blue Cross Affiliate Highmark

  4. Arna Genomics Raises $3.5M In Series A Financing

  5. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.